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Tumour growth is tightly related to new blood vessel formation, tissue remodelling and invasiveness capacity. A number of tissular
factors fuel the growth of glioblastoma multiforme, the most aggressive brain neoplasm. In fact, gene array analyses demonstrated that
the proapoptotic cytokine tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) inhibited mRNA expression of VEGF,
along with those of matrix metalloproteinase-2 (MMP-2), its inhibitor tissue inhibitor of matrix metalloproteinases-2 (TIMP-2), as well
as the tumour invasiveness-related gene secreted protein acid rich in cysteine (SPARC) in different human glioblastoma cell lines.
Particularly, VEGF mRNA and protein expression and release from glioblastoma cells were also inhibited by TRAIL. The latter also
exerted antimitogenic effects on human umbilical vein endothelial cells (HUVECs). With the same cells, TRAIL inhibited new vessel
formation in the in vitro matrigel model, as well as it exerted powerful inhibition of blood vessel formation induced by an angiogenic
cocktail administered in subcutaneous pellets in vivo in the C57 mouse. Moreover, the expression of MMP-2, its inhibitor TIMP-2 and
the tumour invasiveness-related protein SPARC were effectively inhibited by TRAIL in glioblastoma cell lines. In conclusion, our data
indicate that TRAIL inhibits the orchestra of factors contributing to glioblastoma biological aggressiveness. Thus, the TRAIL system
could be regarded as a molecular target to exploit for innovative therapy of this type of tumour.
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Formation of new blood vessels starting from pre-existing vascular
structures is referred to as angiogenesis (Bussolino et al, 1998).
Angiogenesis is dependent on an array of intrinsic stimulatory and
inhibitory factors, interplaying among them with the aim to
modulate both tissue matrix and cells participating in the process
(Risau, 1997).
Vascular endothelial growth factor (VEGF) is the most specific
among proangiogenic factors (Ferrara, 1993), whose expression is
typically increased in normal and tumour cells at conditions of
hypoxia (Ferrara and Davis Smyth, 1997). A quite large number of
tumours are able to synthesise and actively release VEGF (Ferrara,
2005). Although of relevance, VEGF is not the sole factor
concurring to angiogenesis. In fact, an array of regulatory
molecules contributes substantially to the formation of new vessels
(Folkman, 1995). For example, the proinflammatory macrophagic
cytokine tumour necrosis factor-a (TNF-a) possesses direct
proangiogenic properties (Vanderslice et al, 1998), and the TNF-
related apoptosis-inducing ligand (TRAIL) has been shown to
affect the function of endothelial cells (Li et al, 2003).
TRAIL binds the two transmembrane, homotrimeric DR4 and
DR5 death receptors, as well as two decoy receptors and
osteoprotegerin, involved in bone tissue remodelling (Almasan
and Ashkenazi, 2003). Although biological effects of TRAIL were
initially thought to be restricted to its typical tumour cell toxicity
(Sheridan et al, 1997), numerous data report its proapoptotic
effects on normal human cells, including brain cells (Nitsch et al,
2000). Interestingly, human glioblastoma cells, such as A172,
U87MG and U373MG, display differential responsiveness to
TRAIL-related cytotoxicity in vitro and in vivo (Pollack et al,
2001; Nabors et al, 2003; Kasuga et al, 2004), and also release
substantial amounts of VEGF in response to hypoxia (Acker and
Plate, 2004). Moreover, such a high angiogenic potential of
glioblastoma appears associated with high expression of tissue
remodelling-related molecules, such as the matrix metallo-
proteinase-2 (MMP-2) and its inhibitor, named tissue inhibitor
of metalloproteinases-2 (TIMP-2), both concurring, along with
angiogenesis, to tumour growth (Fillmore et al, 2001; VanMeter
et al, 2001). Furthermore, glioblastoma growth is marked by severe
dysfunction of molecules such as the secreted protein acid rich in
cysteine (SPARC), which, in normal cells, restraints invasiveness
and is actually being regarded as a candidate main enhancer of
high tissue invasiveness (Golembieski and Rempel, 2002; Schultz
et al, 2002).
Thus, in light of the reported effects of TRAIL on both tumour
and endothelial cells, considering the high vascularisation index
of glioblastomas (De Ridder et al, 1987), we first investigated
the possible involvement of TRAIL in glioblastoma-related
angiogenesis.
Received 3 January 2006; revised 14 March 2006; accepted 14 March
2006; published online 11 April 2006
*Correspondence: Dr R Bernardini;
E-mail: bernardi@unict.it
British Journal of Cancer (2006) 94, 1428 – 1435
& 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00
www.bjcancer.com
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
To do so, we verified the hypothesis whether TRAIL
could influence angiogenesis-related genes in both the three
human glioblastoma cell lines A172, U87MG and U373MG,
as well as in human umbilical vein endothelial cells (HUVECs),
by means of a specific microarray (Zheng et al, 2000). In parallel,
we also evaluated direct effects of TRAIL on endothelial cell
function.
To verify the hypothesis that factors modulating angiogenesis
might, in addition, influence tissue factors related to tumour
progression, we studied TRAIL effects upon tissue remodelling and
invasiveness gene expression in different glioblastoma cell lines.
MATERIALS AND METHODS
Cell cultures and reagents
All materials and media were from Invitrogen Srl (San Giuliano
Milanese, Italy), unless otherwise specified.
The human glioblastoma cell lines A172, U87MG and U373MG,
as well as both the HeLa and the MCF-7 cell lines, were routinely
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v vÿ1) fetal bovine serum (FBS),
50 mgmlÿ1 penicillin and 100 mgmlÿ1 streptomycin, and kept at
371C in humidified 5% CO2/95% atmosphere.
HUVECs were obtained from human umbilical cords of healthy
women undergone uncomplicated term pregnancies, as described
elsewhere (Jaffe et al, 1973). HUVECs were grown in gelatin-coated
plastic in medium M199 supplemented with endothelial cell
growth supplement (ECGS; 20 mgmlÿ1), heparin (1625UImlÿ1)
(Sigma-Aldrich, Milano, Italy) and 20% FBS.
Gene array
Human Angiogenesis GEArray kit (SuperArray Inc., Bethesda, MD,
USA), composed of 96 angiogenesis-related genes as well as two
housekeeping genes, actin and glyceraldehyde-3-phosphate de-
hydrogenase (GADPH), was used to characterise gene expression
profile of A172 cells after treatment with TRAIL 25 ngmlÿ1 (Alexis
Biochemicals, San Diego, CA, USA) for 0, 6, 12 and 24 h. Total RNA
was isolated from cells after solubilisation in guanidinium
thiocyanate by phenol–chloroform extraction and precipitation.
cDNA probes for array analysis were synthesised following the
manufacturer’s directions. Differential gene expression patterns
were detected by autoradiography. The experiments were repeated
three times.
Probe synthesis and Northern blot analysis
The cDNA probes of the VEGF gene and the GADPH were
synthesised by RT–PCR. For the human VEGF, we used a primer
pair composed of the sense primer 50-TTGCTGCTCTACCTCCAC
-30 and the antisense primer 50-AATGCTTTCTCCGCTCTG-30; for
the human GADPH, the primer set was composed of the sense
50-CCACCCATGGCAAATTCCATG-3’ and antisense 50-TCTAGA
CGGCAGGTCAGGTCCACC-3’. The resulting cDNAs were purified
by High Pure PCR pruduct (Boehringer, Mannheim, Germany)
according to the manufacturer’s protocol. Then, probes were
labelled with [32P]dCTP by random primer labelling. Northern
hybridisation was performed according to standard protocols. The
hybridised RNA was detected by autoradiography.
Data analysis
Scanlyser software developed by Micheal Eisen at Lawrence
Berkeley National Laboratory and GEArray analyser software (by
SuperArray Inc.) were used to analyse the gene spots and process
data. First X-ray film-recorded array images were converted into
raw data files by using scanlyser software. The data files were then
processed with GEArray analyser software. Background subtrac-
tion was performed normalising the data to the negative control
(bacterial plasmid pUC18). The gene expression levels in the
different samples were then normalised to the housekeeping gene
expression level of each array. The results were expressed as
relative amounts in arbitrary units. The data were presented as the
mean7s.e.m. of two different experiments in duplicate.
Western blot analysis
In a set of experiments, subconfluent glioblastoma cell lines grown
in 60mm plastic Petri dishes were starved for 24 h and then
incubated in the presence of TRAIL (25 ngmlÿ1) for 12 and 24 h. In
other experiments, cells grown in 60mm plastic Petri dishes,
starved for 24 h, were incubated in the presence of TRAIL
(25 ngmlÿ1) or TNFa (25 ngmlÿ1) for 24 h, either alone or in
combination. Cells were then lysed in NP-40 lysis buffer (50mM
HEPES, pH 7.6, 150mM NaCl, 50 mM NaF, 2mM EDTA, 1mM
Na3VO4, 1% NP-40, 2mM PMSF) and cellular extracts (30 mg) were
processed for SDS–PAGE electrophoresis and nitrocellulose
membrane transfer. Membranes were incubated with a rabbit
polyclonal anti-hVEGF (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), mouse monoclonal anti-hMMP-2 (Chemicon Inter-
national Inc., Temecula, CA, USA), mouse monoclonal anti-hTIMP-2
(Santa Cruz Biotechnology) or goat polyclonal anti-hSPARC
antibody (Santa Cruz Biotechnology). Secondary antibodies
(Amersham Life Science, Buckinghamshire, UK) and a chemi-
luminescence kit (Amersham) were used for immunodetection.
For validation of blot data, densitometric analysis was performed
on immunoblots by using a KLB 2222-020 Ultra Scan XL laser
densitometer at a wavelength of 633 nm. Western blot analysis was
performed on samples from three separated experiments.
ELISA test
A specific double-antibody ELISA (Oncogene Research Product,
San Diego CA, USA) was used to determine the concentration of
VEGF in the media of different glioblastoma cells treated with
TRAIL (25 ngmlÿ1) for 24 h. The standard curve was generated
using human recombinant VEGF165. The values of intra- and
interassay variation were essentially within the range given by the
manufacturer, that is, 3.5–6.5 and 5.0–8.5%, respectively. All
values were assessed at least in quadruplicate.
Viability assays
A172, U87MG and U373MG human glioblastoma cells were seeded
at 1 103 cells wellÿ1 in 96-multiwell plates containing DMEM,
with 10% FCS, penicillin and streptomycin. After 24 h, TRAIL was
added at graded concentrations (range 12–200 ngmlÿ1) for 24
additional hours.
HUVECs were seeded at 1 103 cells wellÿ1 into 96-multiwell
plates in M199 with ECGS, 20% FBS and heparin. After 24 h,
medium was replaced with fresh complete medium containing
graded concentrations of TRAIL (100, 200 and 400 ngmlÿ1), and
incubated for 24 h.
At the end of all experiments, cells were stained with 0.5%
crystal violet solution for 30min, washed with bidistilled water and
lysed in 10% acetic acid for 15min. Optical density was read at
570 nm.
In vivo experiments on angiogenesis
Male C57BL/6 mice, 6–8 weeks old, were purchased from Charles
River (Calco, Italy). In National Cancer Research Institute’s
Animal Facility, investigators can work with laboratory animals
with respect to the national current regulations regarding the
protection of animals used for scientific purpose (D.L.vo 27/01/
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1992, no. 116) and research protocols were reviewed and approved
by the Ethical Committee. All in vivo procedures met the standards
required by the United Kingdom co-ordinating committee on
cancer research (UKCCCR) guidelines. In addition, the animal
study procedures were consistent and in accordance with the
UKCCCR guidelines for the welfare of animals in experimental
neoplasia (Workman et al, 1998).
The Matrigel sponge model of angiogenesis in vivo introduced
by Passaniti et al (1992) and modified by Albini et al (1994, 1995)
was used. VTH (50 ngmlÿ1 VEGF, 2 ngmlÿ1 TNF-a and heparin)
alone or in combination with TRAIL was added to unpolymerised
liquid Matrigel at 41C, and the mixture brought to a final volume
of 600 ml. The Matrigel suspension was then injected slowly
subcutaneously into the flanks of C57/bl6 male mice (six animals
per group; housed in tight accordance to current GLP regulations
and humane care; these procedures meet the standards required by
the UKCCCR guidelines). In addition, the animal study procedures
were consistent and in accordance with the UKCCCR guidelines
for the welfare of animals in experimental neoplasia (Workman
et al, 1998) with a cold syringe. At body temperature in vivo, the
Matrigel quickly polymerises to form a solid gel. Different groups
of animals were used for the different treatments. The control
group was treated with vehicle alone; one group received TRAIL
high dose (200 ngmlÿ1) with VTH in the Matrigel sponge, whereas
another group received TRAIL low dose (100 ngmlÿ1) with VTH in
the Matrigel sponge.
After 4 days, gels from all groups were collected and weighted.
Samples were either minced and diluted in water to measure the
haemoglobin content with a Drabkin reagent kit (Sigma) or
processed for histology.
Matrigel morphogenesis assay
Matrigel was thawed at 41C in an ice/water bath, and 300ml wellÿ1
were carefully added to a 24-microwell plate prechilled at ÿ201C
using a cold pipette. Matrigel was allowed to polymerise for 30min
at 371C. Once polymerisation had occurred, 70 000 HUVEC
cells wellÿ1 in 1ml of complete medium were layered on the top
of polymerised gel in the presence or absence of TRAIL at the
concentrations indicated. The plates were then incubated at 371C
in a 5% CO2, humidified atmosphere. After 6 and 24 h, the wells
were photographed with CCD optics and a digital analysis system
(Image Pro Plus), respectively.
Statistical analysis of results
Results were analysed by either one- or two-way analysis of
variance (ANOVA), followed by Duncan’s least significant
difference test. Where appropriate, the Student’s ‘t’-test was
applied. Significance was admitted for a P-value o0.05.
RESULTS
Effects of TRAIL on human glioblastoma cell viability
We first assessed TRAIL cytotoxicity on the glioblastoma cell lines
A172, U87MG and U373MG. All glioblastoma cells treated with
graded concentrations of TRAIL showed significant decrease of
viability, reaching a peak at a concentration of 100 ngmlÿ1. All
cells underwent death after 24 h treatment. On the other hand, only
about 25% of cells were killed after 24 h of treatment with TRAIL
(25 ngmlÿ1) (Figure 1A, graphs 1, 2 and 3).
Effects of TRAIL on human glioblastoma cell expression of
genes related to angiogenesis, tissue remodelling and cell
invasiveness
To study the effects of TRAIL on angiogenesis, we first investigated
whether it could affect the expression of angiogenesis-related genes
in glioblastoma cells. To do so, we performed multiple mRNA
screening analysis in A172 cells treated with TRAIL.
The corresponding gene array analysis of A172 human
glioblastoma cells treated with TRAIL showed that the response
to TRAIL encompasses several angiogenesis-related genes.
Particularly, the expression of the following genes was affected
in A172 cells after 24 h of treatment with TRAIL: VEGF, the MMP-
2, the gene encoding TIMP-2, a protein regulating the activity of
MMP-2 and SPARC, a protein involved in glioblastoma invasive-
ness processes (Figure 2A).
Effects of TRAIL upon the angiogenic potential of human
glioblastoma cells: inhibitory effects of TRAIL on VEGF
mRNA and protein
As VEGF expression was affected in A172 cells treated with TRAIL,
we first attempted to measure changes in VEGF mRNA amounts by
Northern blot analysis in cultures treated with TRAIL. The data
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Figure 1 Concentration-related effects of TRAIL on the viability of the human glioblastoma cell lines A172, U87MG or U373MG. Vertical bars are
means7s.e.m. All experiments were run three times in duplicate. *Po0.05 compared to control (one-way ANOVA followed by Duncan’s test).
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obtained showed that VEGF mRNA was reduced after 6, 12 and
24 h of treatment with TRAIL. The effect of TRAIL was time-
related and peak values were observed after 12 h of treatment
(Figure 2B).
Secondly, Western blot analysis showed a reduction in the
amounts of VEGF protein in the three glioblastoma cell lines
treated 24 h with TRAIL (Figure 3A).
In addition, as the VEGF synthesised could not have necessarily
been released in the milieu, we measured VEGF levels in the
culture media of the same samples of glioblastoma cells and
observed that it was actually released in substantial amounts
(Figure 3B).
Nevertheless, the effects of TRAIL described so far appeared
related to its capability of interfering with basal levels of VEGF
protein expressed by A172, U87MG and U373MG cells. As it is
known that angiogenesis is the result of a complex interplay of an
array of different factors, we studied whether such inhibitory effect
of TRAIL could interfere with proangiogenic factor-stimulated
VEGF expression.
Thus, we first induced high VEGF expression by treating A172
cells with TNF-a, a known inducer of VEGF expression (Ferrer
et al, 1997). However, VEGF expression did not increase in the
presence of TNF-a in A172 cells preincubated with TRAIL. The
effect of the latter was time-dependent and reached its peak after
24 h (Figure 3C).
Effects of TRAIL on normal human endothelial cells:
TRAIL affects VEGF synthesis capacity and mitogenesis in
HUVEC cells
Endothelial cells respond to VEGF with mitogenesis, followed by
the organisation of cells in new vessels. VEGF may either be
released in the milieu either by tumour cells or by endothelial cells
themselves. In order to verify whether the effects of TRAIL on
VEGF production by tumour cells are actually concurring with a
general antiangiogenic objective, the angiogenesis-related gene
array analysis was also performed in HUVEC.
VEGF protein expression in HUVEC, which expresses both
TRAIL receptors DR4 and DR5 mRNAs and proteins, was reduced
after 24 h of treatment with TRAIL (Figure 4A), an effect paralleled
by reduced proliferation of endothelial cells (Figure 4B).
TRAIL inhibits vessel formation in vitro and in vivo. To assess
whether the antimitogenic effect of TRAIL on HUVEC encom-
passes actual blood vessel formation, we tested the effects of
TRAIL in appropriate models, such as tube formation in matrigel
in vitro (matrigel morphogenesis assay), as well as vessel
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Figure 2 (A) Inhibition of VEGF, MMP-2, TIMP-2 or SPARC (open bars)
mRNAs after exposure of A172 cells to TRAIL (closed bars), as revealed by
cDNA microarray. mRNA was isolated from cells exposed for 24 h to
25 ngmlÿ1 of TRAIL. The results were expressed as relative amounts in
arbitrary units. All data are the mean7s.e.m. from three different
experiments run in duplicate. *Po0.05 compared to control (one-way
ANOVA followed by Duncan’s test). (B) Northern blot analysis of the
time-related inhibition of VEGF mRNA in A172 glioblastoma cells treated
with 25 ngmlÿ1 of TRAIL. Quantitative analysis was performed normalising
the sample vs GADPH mRNA levels. Time 0 was assumed as a control.
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Figure 3 (A) Western blot analysis of the time course related to inhibition of the 21 kDa VEGF protein in A172, U373MG and U87MG glioblastoma cells
treated with 25 ngmlÿ1 of TRAIL. Time zero was assumed as a control. (B) Amounts of VEGF released into the tissue culture media from either MCF-7,
HeLa or A172, U373MG and U87MG glioblastoma cells incubated 24 h with TRAIL (25 ngmlÿ1). All data are the mean7s.e.m. from three different
experiments run in duplicate. *Po0.05 vs control (zero concentration; one-way ANOVA followed by Duncan’s test). (C) Inhibitory effect of TRAIL upon
the TNF-a-stimulated VEGF expression in A172 glioblastoma cells. TRAIL was added to cultures for 24 h at a concentration of 25 ngmlÿ1. TNF-a was used
at a concentration of 25 ngmlÿ1.
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formation in matrigel sponges containing a proangiogenic cocktail
implanted subcutaneously in vivo in the mouse (inhibition of
angiogenesis in vivo, according to the UKCCCR guidelines;
Workman et al, 1998).
In the matrigel morphogenesis assay, formation of the typical
cellular network occurred 6 h after plating (Figure 4C, photograph
1); TRAIL had concentration-dependent inhibitory effect on the
morphogenesis of HUVEC cells and formation of capillary-like
structures, which peaked at 200 ngmlÿ1 (Figure 4C, photograph 2).
The effects of TRAIL on angiogenesis-associated endothelial cell
functions observed in vitro were confirmed in vivo in the Matrigel
angiogenesis assay. Matrigel suspensions containing a proangio-
genic cocktail with VEGF (50 ngmlÿ1), TNF-a (2 ngmlÿ1) and
heparin (VHT) were injected subcutaneously into mice. The
presence of VTH in the Matrigel sponges promoted a haemor-
rhagic vascularisation of the gels within 4 days (Figure 5A,
photograph 1). Histological examination confirmed the absence
of vascularisation in the samples treated with TRAIL alone
(Figure 5A, photograph 2), or the blunted angiogenesis also in
the presence of the angiogenic cocktail VTH (Figure 5A, photo-
graph 3). Quantification of the extent of angiogenesis by
haemoglobin content measurement showed that TRAIL
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Figure 4 (A) Western blot analysis of the time-dependent effect of TRAIL (100 ngmlÿ1) upon the expression of the 21 kDa VEGF protein in HUVEC
cells. (B) Concentration-dependent viability of HUVEC cultures treated 24 h with graded concentrations of TRAIL. All data are the mean7s.e.m. from three
different experiments run in duplicate. *Po0.05 vs control (zero concentration; one-way ANOVA followed by Duncan’s test). (C) Matrigel morphogenesis
assay in vitro. Tube formation was evaluated in HUVEC cells grown in matrigel and either untreated (control, 1) or treated for 24 h with 200 ngmlÿ1 of
TRAIL (2).
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Figure 5 Matrigel angiogenesis assay in vivo. The figure illustrates the differences in size (cm) of the vascularised areas developed locally in vivo after
stimulation with different substances. All in vivo procedures were performed in accordance to the standards required by the UKCCCR guidelines for the
welfare of animals in experimental neoplasia (Workman et al, 1998). (A) Effect of TRAIL upon vessel formation induced by matrigel sponges containing a
proangiogenic cocktail implanted subcutaneously in vivo in the mouse. Either a proangiogenic cocktail (VTH alone, the six samples shown in A1), TRAIL at a
concentration of 200 ngmlÿ1 (TRAIL alone, the six samples shown in A2), or a combination of both (in A3: VTH alone, the three samples shown in the
upper row; VTHþTRAIL, the three samples in the lower row) was added to matrigel. (B) Vascularisation index calculated on the basis of the inhibitory
effects of TRAIL measured in the matrigel angiogenesis assay in vivo. *Po0.009 (Student’s ‘t’-test for paired differences).
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(200 ngmlÿ1) significantly (Po0.0089; paired t-test) reduced the
angiogenic response if compared to the positive control
(Figure 5B).
Effects of TRAIL on the expression of the MMP-2 and its
inhibitor TIMP-2, and the invasiveness regulator protein
SPARC in human glioblastoma cell lines
The angiogenic process appears closely related to the capacity of
the tumour itself to express local invasiveness. Interestingly, gene
array analysis showed that mRNA levels of both metalloproteinase
MMP-2 and its inhibitor TIMP-2 were reduced in A172, U87MG
and U373MG cells treated for 24 h with TRAIL.
Thus, we first assessed the amounts of intracellular MMP-2 by
Western blot analysis of proteins. The results indicated that TRAIL
induces a time-dependent decrease in intracellular levels of the
enzyme. Peak of TRAIL effect occurred at 24 h (Figure 6, upper
bands).
Along with the MMP-2, we studied the expression of its protein
inhibitor TIMP-2, whose expression was also decreased in the gene
array analysis.
Western blot analysis of TIMP-2 in A172, U87MG and U373MG
cells treated with TRAIL resulted in decreased levels of TIMP-2
protein. The effect of TRAIL was time-dependent. Peak of the
inhibitory effect was at 24 h (Figure 6, middle bands).
The protein SPARC has been regarded as a promoter of local
invasiveness of glioblastoma. As we have shown that TRAIL
decreases angiogenesis as well as remodelling factors, we
attempted to answer the question whether factors controlling
invasiveness could also be affected by TRAIL.
Interestingly, gene array analysis of A172 cells treated with
TRAIL showed that SPARC mRNA was reduced in comparison
with untreated cells.
On the same line, Western blot analysis data showed decreased
amounts of SPARC protein in A172, U87MG and U373MG cells
treated with TRAIL, with a maximal effect at 24 h (Figure 6, lower
bands).
DISCUSSION
We showed that TRAIL, a typical proapoptotic peptide molecule
(Sheridan et al, 1997; Almasan and Ashkenazi, 2003), is a potent
inhibitor of angiogenesis-, tissue remodelling- or invasiveness-
related factors in human glioblastoma cells. In gene array
experiments, we observed that the treatment of A172 human
glioblastoma cells with TRAIL reduced VEGF mRNA expression.
In addition, expression of the tissue remodelling-related gene
MMP-2 and its regulator TIMP-2 was also decreased, along
with the expression of the invasiveness-related protein SPARC.
Northern and Western blot analyses confirmed gene array data,
by showing a decrease in VEGF mRNA in A172 cells, and the
corresponding protein in A172, U87MG and U373MG cells treated
with TRAIL.
Human glioblastoma is a richly vascularised tumour (Zagzag
et al, 2000) that expresses and actively releases in the vicine tissues
substantial amounts of factors promoting new vessel growth
(Guerin and Laterra, 1997). As a counterproof of such biological
attitude of glioblastoma, we also found that VEGF is actively
released by A172, U87MG and U373MG glioblastoma cells in the
tissue culture media.
Thus, from these data, it is plausible to hypothesise that VEGF
released in the milieu probably reaches biologically significant
concentrations, which, in light of its proangiogenic effects (Ferrara
et al, 2003), are functional to maintain blood vessel formation
aimed to fuel tumour enlargement.
Not only were the antiangiogenic effects of TRAIL on
glioblastoma cells related to inhibition of VEGF release by tumour
cells, but these were also extended to endothelial cells.
In fact, TRAIL was able to reduce the expression of VEGF
protein in HUVECs. VEGF produced and released by endothelial
cells is regarded as an ancillary mechanism supporting their own
survival and proliferation in an autocrine fashion (Villegas et al,
2005), as it has been described, for instance, in ischaemic tissues
(Seghezzi et al, 1998).
In addition to its anti-VEGF effect in HUVECs, TRAIL reduced
not only HUVECs’ viability but also their capability of organisation
in primitive vessels, as shown by data indicating TRAIL-dependent
inhibition of vessel formation in vitro and in vivo.
In support of these results, Gochuico et al (2000) described
activation of an intracellular death programme, followed by
apoptosis, in endothelial cells treated with concentrations of
TRAIL in the range of hundreds of nanograms per millilitre, which
have been shown to induce apoptosis in a variety of cells
(Puduvalli et al, 2005; Shiraki et al, 2005). Thus, the apparent
discrepancy of ours with other data demonstrating a mitogenic
effect of TRAIL upon human endothelial cells (Secchiero et al,
2004) could be explained on the basis of the significantly lower
(about 10-fold; 10 ngmlÿ1) concentrations used.
In fact, it has been demonstrated that low concentrations of
TRAIL activate signal-transduction pathways related, respectively,
to ERKs and Akt, the latter depending upon PI3K activation
(Secchiero et al, 2003), whereas p38K is not activated. Besides,
TRAIL at a concentration of 100 ngmlÿ1 induces apoptosis in
combination with the PI3K inhibitor LY294002 in human vascular
endothelial cells through activation of the extrinsic pathway,
TRAIL
24 h12 hCTRL
TIMP-2
U87MG
U373MG
A172
SPARC
U87MG
U373MG
A172
MMP-2
U87MG
U373MG
A172
Figure 6 Western blot analysis of the inhibitory, time-dependent effects
of TRAIL (25 ngmlÿ1) upon the expression of MMP-2 (upper panel), its
inhibitor TIMP-2 (middle panel) and SPARC (lower panel) proteins in
cultured A172, U373MG and U87MG human glioblastoma cell lines.
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causing progressive cleavage of caspase-8 and caspase-3 with
concurrent reduction of the antiapoptotic gene bcl-2 and early loss
of the short form of the cellular FLIP (Alladina et al, 2005).
At any rate, we were also able to show the antiangiogenic effect
of TRAIL in various in vitro models. To strenghten the hypothesis
that TRAIL possessed antiangiogenic properties, we have also
shown that it displays antagonistic activity upon proangiogenic
cocktail-stimulated vessel formation in vivo in the mouse.
Evidence suggests that the angiogenic process is associated with
a complex network of cellular and molecular events related to
tissue remodelling (Sounni et al, 2002) and tumour tissue
invasiveness (Nakada et al, 2003).
The human glioblastoma cell lines A172, U87MG and U373MG
expressed substantial amounts of the MMP-2 (Chintala et al, 1999),
which were decreased after treatment with TRAIL.
Tissue metalloproteinases, such as MMP-2, appear specifically
involved in tissue remodelling. In fact, it has been shown that their
expression is significantly increased in inflammation (Shamamian
et al, 2001) and in tumour invasiveness and metastatisation (Turck
et al, 1996) processes. Metalloproteinases are in turn regulated by
inhibitory molecules (Goldman and Shalev, 2004); the balance
between the two molecular families being critical for control of
proteolysis (Lu et al, 2004).
Interestingly, the A172, U87MG and U373MG glioblastoma cell
lines expressed high levels of the TIMP-2 metalloproteinase
inhibitor and TRAIL was able to reduce such expression. Although
divergent data are available regarding relationships between the
expression of MMPS and the inhibitory TIMP protein family in
gliomas, a number of reports claim that, along with that of MMP,
TIMP overexpression is closely related to the degree of malignancy
(Nakano et al, 1995; Lampert et al, 1998).
Overall, the bulk of data demonstrate that an altered ratio
between TIMP-2 and MMP-2 may be related to glioblastoma
invasiveness (Kachra et al, 1999).
It could be reasoned that the inhibitory effect of TRAIL upon the
metalloproteinase system is added to its antiangiogenic effects
reported earlier. In fact, factors controlling tumour invasiveness
act in a concerted way with those related to both angiogenesis and
tissue remodelling (Finn et al, 1997). Interestingly, gene array data
from cells treated with TRAIL showed decreased expression of
the invasiveness inhibitor protein SPARC. Although the latter
normally inhibits cell invasiveness processes (Hasselaar and Sage,
1992), it displays opposite effects in tumour cells (Briggs et al,
2002), including glioblastoma (Vajkoczy et al, 2000). For this
reason, SPARC has been regarded as an enhancer of the capability
of glioblastomas to localise in multiple sites of the brain (Schultz
et al, 2002).
In summary, TRAIL is a potent inhibitor of the orchestra of
factors controlling angiogenesis, invasiveness and tissue remodel-
ling in various human glioblastoma cell lines. The antiangiogenic
effects of TRAIL include inhibition of VEGF release from tumour
cells, as well as an antimitogenic effect upon endothelial cells. In
addition, TRAIL potently suppresses the expression of tissue
remodelling factors, such as MMP-2 and TIMP-2, as well as of
those promoting glioblastoma invasiveness, such as SPARC.
In conclusion, the TRAIL system could be regarded as a
potential target for novel glioblastoma therapy aimed at disruption
of the ensemble of factors promoting angiogenesis, tissue
remodelling and tumour invasiveness.
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